Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2344346 | 0.92 | TSHR (0.52) | TSHRCYP1A2CYP3A4TDP1ALDH1A1 | |
| SCHEMBL29536425 | 0.92 | TSHR (0.52) | TSHRCYP1A2CYP3A4TDP1ALDH1A1 | |
| Potassium Ion SCHEMBL3390956 | 0.89 | TSHR (0.49) | TSHRCYP1A2CYP3A4TDP1ALDH1A1 | |
| SCHEMBL30291047 | 0.86 | CYP1A2 (0.53) | TSHRCYP1A2CYP3A4TDP1ALDH1A1 | |
| SCHEMBL18398966 | 0.86 | CYP1A2 (0.53) | TSHRCYP1A2CYP3A4TDP1ALDH1A1 | |
| SCHEMBL10488867 | 0.86 | TSHR (0.57) | TSHRCYP1A2CYP3A4TDP1ALDH1A1 | |
| SCHEMBL348272 | 0.84 | TSHR (0.59) | TSHRCYP1A2CYP3A4TDP1ALDH1A1 | |
| SCHEMBL11553055 | 0.84 | ALDH1A1 (0.53) | TSHRCYP1A2CYP3A4TDP1ALDH1A1 | |
| SCHEMBL7653551 | 0.84 | ALDH1A1 (0.53) | TSHRCYP1A2CYP3A4TDP1ALDH1A1 | |
| SCHEMBL9652342 | 0.82 | TSHR (0.57) | TSHRCYP1A2CYP3A4TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9287568-B2 | High performance, high durability non-precious metal fuel cell catalysts | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-03-15 | — | — | US | claimed |
| CN-101657921-B | High performance, high durability non-precious metal fuel cell catalysts | 3M INNOVATIVE PROPERTIES CO US | 2013-06-12 | — | — | CN | claimed |
| US-20110319257-A1 | HIGH PERFORMANCE, HIGH DURABILITY NON-PRECIOUS METAL FUEL CELL CATALYSTS | 3M INNOVATIVE PROPERTIES COMPANY | 2011-12-29 | — | — | US | claimed |
| EP-2135313-B1 | HIGH PERFORMANCE, HIGH DURABILITY NON-PRECIOUS METAL FUEL CELL CATALYSTS | 3M INNOVATIVE PROPERTIES CO (US) | 2011-09-14 | — | — | EP | claimed |
| CN-101657921-A | High-performance, high durability non-precious metal fuel cell catalysts | 3M INNOVATIVE PROPERTIES CO US | 2010-02-24 | — | — | CN | claimed |
| EP-4466258-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2024-11-27 | — | — | EP | disclosed |
| US-20240383875-A1 | Benzimidazole Pyridine Derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| CN-118591534-A | Novel benzimidazole pyridine derivatives | 豪夫迈·罗氏有限公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2023139085-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| US-9957236-B2 | Selective inhibitors interfering with fibroblast growth factor receptor and FRS2 interaction for the prevention and treatment of cancer and other diseases | LIMITED LIABILITY COMPANY “RUSSIAN PHARMACEUTICAL TECHNOLOGIES” (RU) | 2018-05-01 | — | — | US | disclosed |
| US-9957236-B2 | Selective inhibitors interfering with fibroblast growth factor receptor and FRS2 interaction for the prevention and treatment of cancer and other diseases | LIMITED LIABILITY COMPANY “RUSSIAN PHARMACEUTICAL TECHNOLOGIES” (RU) | 2018-05-01 | — | — | US | disclosed |
| US-20170183315-A1 | SELECTIVE INHIBITORS INTERFERING WITH FIBROBLAST GROWTH FACTOR RECEPTOR AND FRS2 INTERACTION FOR THE PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES | LIMITED LIABILITY COMPANY "RUSSIAN PHARMACEUTICAL TECHNOLOGIES" (RU) | 2017-06-29 | — | — | US | disclosed |
| WO-2011126567-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| EP-2135313-B1 | HIGH PERFORMANCE, HIGH DURABILITY NON-PRECIOUS METAL FUEL CELL CATALYSTS | 3M INNOVATIVE PROPERTIES CO (US) | 2011-09-14 | — | — | EP | disclosed |
| CN-101657921-A | High-performance, high durability non-precious metal fuel cell catalysts | 3M INNOVATIVE PROPERTIES CO US | 2010-02-24 | — | — | CN | disclosed |
| EP-2135313-A1 | HIGH PERFORMANCE, HIGH DURABILITY NON-PRECIOUS METAL FUEL CELL CATALYSTS | 3M Innovative Properties Company (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008127828-A1 | HIGH PERFORMANCE, HIGH DURABILITY NON-PRECIOUS METAL FUEL CELL CATALYSTS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-10-23 | — | — | WO | disclosed |
| EP-1606268-A1 | HETEROCYCLIC KINASE INHIBITORS | Abbott Laboratories (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040254159-A1 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES | 2004-12-16 | — | — | US | disclosed |
| WO-2004076424-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254159-A1 | Heterocyclic kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | TSHR 4139/4885CYP1A2 2785/4885CYP3A4 3138/4885 |
| US-20240383875-A1 | Benzimidazole Pyridine Derivatives | H1-3, H1-2, H1-4 | TSHR 792/4885CYP1A2 8/4885CYP3A4 23/4885 |
| US-20170183315-A1 | SELECTIVE INHIBITORS INTERFERING WITH FIBROBLAST GROWTH FACTOR RECEPTOR AND FRS2 INTERACTION FOR THE PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES | FRS2, FGFR2, FGFR1 | TSHR 443/4885CYP1A2 4431/4885CYP3A4 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.